AR127816A1 - CORONAVIRUS VACCINE FORMULATIONS - Google Patents
CORONAVIRUS VACCINE FORMULATIONSInfo
- Publication number
- AR127816A1 AR127816A1 ARP220103285A ARP220103285A AR127816A1 AR 127816 A1 AR127816 A1 AR 127816A1 AR P220103285 A ARP220103285 A AR P220103285A AR P220103285 A ARP220103285 A AR P220103285A AR 127816 A1 AR127816 A1 AR 127816A1
- Authority
- AR
- Argentina
- Prior art keywords
- nanoparticles
- cell
- vaccine formulations
- vaccines
- nucleic acid
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 241000711573 Coronaviridae Species 0.000 title 1
- 239000002105 nanoparticle Substances 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 241000238631 Hexapoda Species 0.000 abstract 1
- 101710167605 Spike glycoprotein Proteins 0.000 abstract 1
- 101710198474 Spike protein Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003599 detergent Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
En la presente se divulgan proteínas de la espícula y nanopartículas que la comprenden, que son adecuadas para el uso en vacunas. Las nanopartículas presentan antígenos de patógenos que rodean y están asociados con un núcleo detergente que da como resultado una estabilidad mejorada y una buena inmunogenicidad. También se divulgan las dosificaciones, formulaciones y métodos para preparar las vacunas y las nanopartículas. Reivindicación 18: Un ácido nucleico que comprende una glicoproteína S de CoV de acuerdo con cualquiera de las reivindicaciones 1 - 17. Reivindicación 20: Un vector que comprende el ácido nucleico de acuerdo con la reivindicación 18 o 19. Reivindicación 34: La célula de acuerdo con la reivindicación 33, en donde la célula es una célula de insecto.Disclosed herein are spike proteins and nanoparticles comprising them, which are suitable for use in vaccines. The nanoparticles present pathogen antigens surrounding and associated with a detergent core resulting in improved stability and good immunogenicity. The dosages, formulations and methods for preparing the vaccines and nanoparticles are also disclosed. Claim 18: A nucleic acid comprising a CoV S glycoprotein according to any of claims 1 - 17. Claim 20: A vector comprising the nucleic acid according to claim 18 or 19. Claim 34: The cell according to with claim 33, wherein the cell is an insect cell.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063332530P | 2020-04-19 | 2020-04-19 | |
| US202063367678P | 2020-07-05 | 2020-07-05 | |
| US202063292120P | 2020-12-21 | 2020-12-21 | |
| US202063293519P | 2020-12-23 | 2020-12-23 | |
| US202163284497P | 2021-11-30 | 2021-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127816A1 true AR127816A1 (en) | 2024-02-28 |
Family
ID=90220636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220103285A AR127816A1 (en) | 2020-04-19 | 2022-11-30 | CORONAVIRUS VACCINE FORMULATIONS |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR127816A1 (en) |
-
2022
- 2022-11-30 AR ARP220103285A patent/AR127816A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009167A (en) | Coronavirus vaccine formulations. | |
| ES2129386T1 (en) | INFLUENZA VACCINE. | |
| BR112022014837A2 (en) | RNA VACCINES AGAINST CORONA VIRUS | |
| MX2024006589A (en) | CORONAVIRUS VACCINE FORMULATIONS. | |
| ES2139553T1 (en) | REPLICATION OF INFLUENZA VIRUSES IN A CULTIVATION OF MAMMALIAN CELLS AND VACCINE PRODUCTION. | |
| GT200200139A (en) | MYCOPLASMA BOVIS VACCINE AND METHODS TO REDUCE PNEUMONIA IN ANIMALS | |
| MX2023006203A (en) | Novel vaccines against zika virus. | |
| EA200900784A1 (en) | VACCINES INCLUDING ANTIGENS FROM FOUR STRAINS OF THE INFLUENZA VIRUS | |
| BR112023019301A2 (en) | CORONAVIRUS VACCINE FORMULATIONS | |
| NO20023829D0 (en) | Proteosome influenza vaccine | |
| BR112018004242A2 (en) | vaccine compositions having increased stability and immunogenicity | |
| MX2010007461A (en) | Novel vaccines against multiple subtypes of dengue virus. | |
| CO6460752A2 (en) | IMMUNE RESPONSE REINFORCED IN AVIAN SPECIES | |
| BR112022016992A2 (en) | VACCINE BASED ON RECOMBINANT POXVIRUS AGAINST SARS-COV-2 VIRUS | |
| CO6140071A2 (en) | MAPACHE POXVIRUS EXPRESSING RABY GLICOPROTEINS | |
| BR112022025733A2 (en) | RECOMBINANT HVT VECTORS EXPRESSING INFLUENZA HEMAGGLUTININ AND IMMUNOGENIC COMPOSITIONS, AND PRODUCTION AND USES THEREOF | |
| Kapczynski et al. | Development of a virosome vaccine for Newcastle disease virus | |
| AR127816A1 (en) | CORONAVIRUS VACCINE FORMULATIONS | |
| AR081409A1 (en) | RECOMBINING PARAPOXVIRUS CONTAINING HETEROLOGICAL DNA DERIVED FROM A RABIA VIRUS (RV) | |
| MX2023000663A (en) | Immunogenic constructs, compositions, and methods for inducing immune response. | |
| BR112015013625A2 (en) | vaccination adjuvant, preparation and vaccines containing the same | |
| AR121151A1 (en) | FORMULATIONS FOR VACCINE AGAINST CORONAVIRUS | |
| ECSP14023407A (en) | MODIFIED MAREK'S DISEASE VIRUS AND VACCINES MADE WITH IT | |
| Lutz et al. | Advanced nanobiomedical approaches to combat coronavirus disease of 2019 | |
| Banerji et al. | RNA vaccines: the evolution, applications, and the challenges ahead |